PDCD1 and glioblastoma: In newly diagnosed MGMT-unmethylated GBM, nivolumab (anti-PD-1) monotherapy showed no increased survival benefit when compared to TMZ after radiation and surgical resection (median overall survival was 14.9 months in the TMZ arm compared to 13.4 months in the nivolumab arm) (NCT02617589).